Clinical trial · Observational
Non-Invasive Diagnosis and Monitoring of Cardiac Masses by Liquid Biopsy
Non-Invasive Diagnosis and Monitoring of Cardiac Masses by Liquid Biopsy: The CarMA Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a nonprofit, observational, prospective and retrospective,multicenter study in a population of young and adult patients ≥12 years with a diagnosis of a cardiac mass. The study will include both patients with masses of unknown pathological diagnosis and patients with a known histology of benign or malignant tumors. We predict a case-control allocation ratio of 1:1 between cardiac malignant tumors and benign lesions. Peripheral blood will be collected at participating centers during routine venipuncture,processed and then shipped for liquid biopsy ctDNA NGS analyses. If available, in malignant cases, matched tumor tissue samples collected as per clinical practice solid biopsies or surgery will be used for analyses. Longitudinal tracking through serial blood draws could be performed in selected cases of patients with cardiac malignancies who receive cancer treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiac Masses | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NGS-guided regimen: Regimen A | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- benign cardiac lesions
- description
- patients diagnosed with benign cardiac lesions
- interventionNames
- Genetic: NGS-guided regimen: Regimen A
- label
- primary cardiac sarcomas
- description
- patients diagnosed with primary cardiac sarcomas (PCS)
- interventionNames
- Genetic: NGS-guided regimen: Regimen A
Primary outcomes (1)
- measure
- Molecular profile
- timeFrame
- Jul2024-Jul2029
- description
- Collect and analyse blood and tissue samples from both cases and control in terms of molecular profile
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria 1. Age ≥12 years old 2. Suspected or confirmed diagnosis of a cardiac mass of any nature as assessed by standard clinical, radiological and/or pathological procedures. Exclusion Criteria 1\. Inability of the pa ent to fully understand and sign the informed consent.
References
Publications (0)
Data not yet available